<DOC>
	<DOCNO>NCT02663622</DOCNO>
	<brief_summary>This multicenter prospective randomize phase IIa/IIb clinical trial design determine MTD ( Maximum Tolerated Dose ) CD24Fc acute GVHD ( Graft Versus Host Disease ) prophylaxis .</brief_summary>
	<brief_title>A Phase II Trial CD24Fc Prevention Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>A prospective patient allogeneic HCT malignant hematologic disorder The donor recipient must HLA8/8 allelic match HLAA , B , C , DRB1 locus . Highresolution type require allele . Only match unrelated donor acceptable trial . The following diagnosis include : 1 . Acute Myeloid Leukemia ( AML ) Acute Lymphoblastic Leukemia ( ALL ) first second remission . Remission define absence blast peripheral circulation time enrollment , &lt; 5 % blast bone marrow absence extramedullary disease include CNS involvement . 2 . Chronic Myelogenous Leukemia ( CML ) first subsequent chronic phase fail respond ( intolerant ) least two different tyrosine kinase inhibitor . CML accelerate blast phase ( CMLAP/BP ) eligible without requirement fail tyrosine kinase inhibitor therapy , must remission time enrollment . Remission define absence blast peripheral circulation time enrollment , &lt; 5 % blast bone marrow absence extramedullary disease include CNS involvement . 3 . Myelodysplastic syndrome ( MDS ) intermediate highrisk IPSS equivalent IPSSR score &lt; 10 % blast bone marrow 4 . Chronic Myelomonocytic Leukemia ( CMML ) &lt; 10 % blast bone marrow Males nonpregnant , nonlactating female , â‰¥ 18 year age Karnofsky &gt; 70 % ( attempt quantify cancer patient ' general wellbeing activity daily life . The score range 0 100 100 `` perfect '' health 0 death . ) Patients must normal near normal organ function define treat institution BMT program clinical practice guideline . Ability understand willingness sign write informed consent document Women child bear potential men must agree use contraception prior study entry day 100 post HCT . Subjects may presence active CNS disease extramedullary disease . Prior cytotoxic chemotherapy within 21 day initiation HCT conditioning . Note , certain low intensity treatment intend induce remission rather stabilize disease acceptable 7 day prior initiation HCT conditioning Matched sibling , cord blood haploidentical donor eligible . HLAmismatch HLAA , B , C , DRB1 locus . Note , HLADQ mismatch permissible Pregnant nursing mother exclude study . Any physical psychological condition , opinion investigator , would pose unacceptable risk patient raise concern patient would comply protocol procedure Uncontrolled infection Patients seropositive PCR positive human immunodeficiency virus ( HIV ) . Patients evidence Hepatitis B Hepatitis C PCR positivity Prior HCT ( allograft prior autograft ) Use T cell depletion either ex vivo vivo ( i.e . ATG , alemtuzumab ) prohibit . 4.2.11 Current prior diagnosis antecedent Myelofibrosis exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>